4MT9

Co-crystal structure of tankyrase 1 with compound 49


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2 Å
  • R-Value Free: 0.258 
  • R-Value Work: 0.212 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.

Hua, Z.Bregman, H.Buchanan, J.L.Chakka, N.Guzman-Perez, A.Gunaydin, H.Huang, X.Gu, Y.Berry, V.Liu, J.Teffera, Y.Huang, L.Egge, B.Emkey, R.Mullady, E.L.Schneider, S.Andrews, P.S.Acquaviva, L.Dovey, J.Mishra, A.Newcomb, J.Saffran, D.Serafino, R.Strathdee, C.A.Turci, S.M.Stanton, M.Wilson, C.Dimauro, E.F.

(2013) J.Med.Chem. 56: 10003-10015

  • DOI: 10.1021/jm401317z
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Tankyrases (TNKS1 and TNKS2) are proteins in the poly ADP-ribose polymerase (PARP) family. They have been shown to directly bind to axin proteins, which negatively regulate the Wnt pathway by promoting β-catenin degradation. Inhibition of tankyrases ...

    Tankyrases (TNKS1 and TNKS2) are proteins in the poly ADP-ribose polymerase (PARP) family. They have been shown to directly bind to axin proteins, which negatively regulate the Wnt pathway by promoting β-catenin degradation. Inhibition of tankyrases may offer a novel approach to the treatment of APC-mutant colorectal cancer. Hit compound 8 was identified as an inhibitor of tankyrases through a combination of substructure searching of the Amgen compound collection based on a minimal binding pharmacophore hypothesis and high-throughput screening. Herein we report the structure- and property-based optimization of compound 8 leading to the identification of more potent and selective tankyrase inhibitors 22 and 49 with improved pharmacokinetic properties in rodents, which are well suited as tool compounds for further in vivo validation studies.


    Organizational Affiliation

    Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, §Oncology Research, ∥Department of Molecular Structure, ⊥Bioassay and Profiling, and #Pharmaceutics, Amgen Inc. , 360 Binney Street, Cambridge, Massachusetts 02142, United States.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Tankyrase-1
A, B
217Homo sapiensMutation(s): 0 
Gene Names: TNKS (PARP5A, PARPL, TIN1, TINF1, TNKS1)
EC: 2.4.2.30
Find proteins for O95271 (Homo sapiens)
Go to Gene View: TNKS
Go to UniProtKB:  O95271
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
ZN
Query on ZN

Download SDF File 
Download CCD File 
A, B
ZINC ION
Zn
PTFCDOFLOPIGGS-UHFFFAOYSA-N
 Ligand Interaction
2D6
Query on 2D6

Download SDF File 
Download CCD File 
A, B
N-[trans-4-(4-cyanophenoxy)cyclohexyl]-3-[(4-oxo-3,4-dihydroquinazolin-2-yl)sulfanyl]propanamide
C24 H24 N4 O3 S
MCMCBDOVNWSRNM-UAPYVXQJSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
2D6IC50: 0.1 nM BINDINGMOAD
2D6IC50: 0.1 nM PDBBIND
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2 Å
  • R-Value Free: 0.258 
  • R-Value Work: 0.212 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 42.007α = 90.00
b = 76.784β = 90.00
c = 148.616γ = 90.00
Software Package:
Software NamePurpose
HKL-2000data collection
HKL-2000data reduction
HKL-2000data scaling
AMoREphasing
CNSrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2013-09-19 
  • Released Date: 2013-12-25 
  • Deposition Author(s): Huang, X.

Revision History 

  • Version 1.0: 2013-12-25
    Type: Initial release
  • Version 1.1: 2014-02-05
    Type: Database references